Summary of Zoetis 2026 Conference Call Company Overview - **Company**: Zoetis (NYSE: ZTS) - **Date**: March 17, 2026 - **Speaker**: Kristin Peck, CEO Key Points Industry and Company Guidance - **2026 Guidance**: Zoetis is guiding for 3.5% organic constant currency growth after achieving 6% in 2025 [1] - **Growth Drivers**: The growth will be driven by a diverse portfolio, particularly in core therapeutic areas such as dermatology, parasiticides, and pain management [2][3] - **Livestock Growth**: Historically, livestock growth has been around 2%-4%, but Zoetis has seen mid- to high-single-digit growth over the past three years and expects to outperform the market in 2026 [3] Financial Metrics - **Price and Volume Assumptions**: The company expects 2%-3% growth from price increases and the remainder from volume for 2026 [5] - **Vet Clinic Visits**: Despite a decline in visits, spending at vet clinics grew by 6% in Q4 2025, indicating a strong human-animal bond and willingness to spend on pet care [10][11] Competitive Landscape - **Market Competition**: Increased competition in dermatology and parasiticides is expected, but Zoetis remains confident in its brand loyalty and customer satisfaction [57][58] - **New Products**: The company is focusing on long-acting pain products and expects to launch new therapies in oncology, cardiology, and renal health, which are anticipated to be high-value markets [19][20][21] Supply Chain and External Factors - **Impact of Oil Prices**: The ongoing conflict in Iran has minimal direct sales impact (less than 1% of total sales), but rising oil prices could affect shipping costs [7][9] - **Weather Impact**: Q1 2026 has seen adverse weather conditions affecting the parasiticide market, which typically performs better in Q2 and Q3 [55][56] Innovation and R&D - **AI in Drug Discovery**: Zoetis is leveraging AI for early drug discovery and molecule selection, utilizing unique datasets that include clinical trial data and genetic information [49][50][51] - **Future Products**: The company is optimistic about the potential of new products in renal health, which is projected to be a $3-$4 billion market, contingent on improved diagnostic rates [20][31] Market Trends - **Protein Demand**: The growing global population and middle-class expansion are driving protein demand, with poultry, fish, and pork being the fastest-growing sources [35][36] - **Health and Wellness Trends**: An aging population is increasing the focus on health and wellness, which is expected to support protein consumption trends [44] Strategic Changes - **Field Team Restructuring**: Zoetis has restructured its go-to-market teams to enhance reach and frequency, focusing on specialty products and chronic care [46][48] Long-Term Outlook - **2030 Vision**: Zoetis aims to continue growing its core franchises while exploring new therapeutic areas, emphasizing the importance of portfolio diversity and innovation [60][61] Additional Insights - **Customer Satisfaction**: High customer satisfaction rates (80%-90%) for key products like Apoquel and Simparica indicate strong brand loyalty [14][58] - **Veterinary Engagement**: The company is investing in professional service vets to enhance scientific conversations and support the growth of specialty products [48] This summary encapsulates the key insights and strategic directions discussed during the Zoetis 2026 conference call, highlighting the company's growth prospects, competitive landscape, and innovation strategies.

Core Viewpoint - Dividend stocks vary significantly, with some companies maintaining or increasing dividends during economic downturns, making them attractive to income-oriented investors. Johnson & Johnson and Zoetis are highlighted as strong candidates for such investors. Group 1: Johnson & Johnson - Johnson & Johnson is characterized by a consistent and resilient business model, being a leading pharmaceutical company with a diverse portfolio of approved medicines and medical devices [3] - The company anticipates annual reported sales to exceed $100 billion for the first time, despite facing challenges like patent cliffs and government drug price negotiations [4] - Johnson & Johnson boasts a strong balance sheet, with a higher credit rating than the U.S. government, and a gross margin of 67.97% [6] - The company is recognized as a Dividend King, having increased its dividends for at least 50 consecutive years, making it a reliable choice for dividend investors [8] Group 2: Zoetis - Zoetis is a leading animal health company that faced challenges last year due to safety concerns regarding its products Librela and Solensia, which treat osteoarthritis pain in pets [9] - The company has received approval for new products, Lenivia and Portela, which are longer-acting treatments and expected to capture market share [10] - Zoetis has a strong growth portfolio, including Apoquel, a breakthrough medicine for allergic itch in dogs, with significant growth potential due to a large untreated population [12] - The company has increased its dividend by 458% over the past decade, positioning it as a strong dividend stock for long-term investment [13]

Core Viewpoint - Zoetis Inc. reported strong fourth-quarter results for 2025, exceeding earnings expectations and demonstrating resilience across its product portfolio despite challenges in certain segments [1][5]. Financial Performance - Adjusted earnings per share for Q4 2025 were $1.48, surpassing the consensus estimate of $1.40 [1]. - Total sales reached $2.387 billion, reflecting a 3% year-over-year increase, closely aligning with the consensus of $2.36 billion [1]. - Adjusted net income was $648 million, marking a 3% increase on a reported basis and a 4% increase on an organic operational basis [1][2]. Segment Breakdown - U.S. segment revenue was $1.2 billion, down 2% on a reported basis but flat on an organic operational basis [3]. - Companion animal product sales decreased by 1%, with declines in monoclonal antibody products for osteoarthritis partially offset by growth in parasiticides and dermatology [3]. - Livestock product sales declined by 6% on a reported basis due to divestitures, but increased by 3% on an organic operational basis, driven by growth in cattle and poultry biologics [4]. Future Guidance - For fiscal 2026, Zoetis forecasts adjusted earnings of $7.00-$7.10 per share, exceeding the consensus of $6.80 [6]. - Sales projections for 2026 are between $9.83 billion and $10.03 billion, compared to the consensus of $9.91 billion [6]. Analyst Outlook - Analysts from William Blair noted that the 2026 EPS guidance is above market expectations, suggesting potential stabilization in fundamentals [7]. - Concerns were raised regarding growth in key segments such as dermatology and OA pain, which experienced a decline [7][8]. - The competitive landscape is expected to intensify, raising questions about growth and EPS improvement in 2026 [8].

Core Insights - Zoetis, Inc. (ZTS) reported fourth-quarter 2025 adjusted earnings of $1.48 per share, exceeding the Zacks Consensus Estimate of $1.40, and up from $1.40 in the same quarter last year [1] - Total revenues for the quarter increased by 3% year over year to $2.39 billion, surpassing the Zacks Consensus Estimate of $2.37 billion, compared to $2.32 billion in the prior year [1] Financial Performance - U.S. segment revenues decreased by 2% year over year to $1.24 billion, missing the Zacks Consensus Estimate of $1.27 billion [3] - Sales of companion animal products in the U.S. declined by 1% year over year to $1 billion, with growth in parasiticides and dermatology products offset by a decline in monoclonal antibody products for osteoarthritis pain [4] - Livestock product sales in the U.S. fell by 6% to $234 million, primarily due to the divestiture of the medicated feed additive product portfolio [6] - International segment revenues grew by 8% year over year to $1.12 billion, exceeding the Zacks Consensus Estimate of $1.06 billion [8] - Ex-U.S. sales of companion animal products rose by 7% to $599 million, driven by growth in key products [8] - Livestock product sales internationally increased by 9% to $522 million, supported by growth across core species [9] Full-Year Results and Guidance - For the full year 2025, Zoetis reported adjusted earnings of $6.41 per share, up from $5.92 the previous year, and total revenues of $9.47 billion, an increase of 2% year over year [10] - The company provided guidance for 2026, expecting adjusted earnings in the range of $7.00-$7.10 per share and revenues between $9.825 billion and $10.025 billion, indicating operational growth of 3-5% [11][13] Product Developments - Zoetis received EU approval for Lenivia, a long-acting monoclonal antibody therapy for canine osteoarthritis pain, with a commercial launch expected in 2026 [14] - The approval of Lenivia is anticipated to enhance Zoetis' position in the companion-animal biologics market and expand its offerings in the osteoarthritis segment [15]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported global revenue of $9.5 billion, growing 2% on a reported basis and 6% on an organic operational basis, with 4% from price and 2% from volume [21][22] - Adjusted net income grew 6% on a reported basis and 7% on an organic operational basis to $2.8 billion [21][22] - Full year adjusted gross margin of 71.9% grew 120 basis points on a reported basis, with foreign exchange having a favorable impact of 80 basis points [39] Business Line Data and Key Metrics Changes - The companion animal portfolio grew 5% operationally, with the Simparica franchise reporting $1.5 billion in revenue, growing 12% operationally [22][24] - The livestock portfolio achieved $2.8 billion in revenue, reflecting 8% organic operational growth, driven by broad-based growth across geographies and species [24][30] - Companion animal diagnostics delivered 13% operational revenue growth, supported by the launch of new products like Vetscan OptiCell and Imagyst [16][23] Market Data and Key Metrics Changes - International markets contributed significantly, with 8% organic operational revenue growth, while the U.S. delivered 4% organic operational growth [7][21] - International companion animal revenue grew 7% operationally, driven by the Simparica and key dermatology franchises [28] - The international livestock portfolio grew 10% on an organic operational basis, with strong performance in cattle and poultry markets [30] Company Strategy and Development Direction - The company is focused on advancing long-acting approvals and maintaining a robust pipeline to extend growth opportunities [8][19] - Strategic actions are being taken to sustain growth through competition, including optimizing channel mix and reinforcing scientific leadership [9][20] - The company aims to leverage its diverse portfolio and robust pipeline, with 12 potential blockbusters in development [19][20] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are economic pressures affecting pet owners, demand for animal health services remains strong [10][71] - The company expects gradual improvement in the macro environment as it moves through 2026, with guidance for 2026 set at 3%-5% organic operational revenue growth [18][42] - Management emphasized the importance of innovation and strategic execution in navigating competitive pressures [19][20] Other Important Information - The company completed a convertible bond offering to support a $1.75 billion common stock buyback while maintaining a strong balance sheet [42] - A multi-year initiative to transition the ERP system is underway to enhance operational efficiency and reporting capabilities [38] Q&A Session Summary Question: Competition and Pricing Dynamics for 2026 - Management acknowledged the competitive landscape and the impact of aggressive promotions on growth, particularly in the dermatology space [50][51] - Price increases are expected to return to a normal range of 2%-3%, with volume contributing to growth as well [52] Question: U.S. Companion Animal Operational Growth - The guidance incorporates current market conditions and the company's strong portfolio, with expectations for continued demand despite competitive pressures [55][56] Question: Dynamics of Simparica Trio Growth - Management highlighted the significant room for expansion in the triple combination space, with expectations for continued growth in 2026 [62] Question: Revenue Recognition and Accounting Changes - Management clarified that operational changes have resulted in some revenue deferrals, which will be factored into future guidance [61][63]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported global revenue of $9.5 billion, growing 2% on a reported basis and 6% on an organic operational basis, with 4% from price and 2% from volume [21][22] - Adjusted net income grew 6% on a reported basis and 7% on an organic operational basis to $2.8 billion [21][22] - Full year adjusted gross margin of 71.9% grew 120 basis points on a reported basis, with foreign exchange having a favorable impact of 80 basis points [39] Business Line Data and Key Metrics Changes - The companion animal portfolio grew 5% operationally in 2025, with the Simparica franchise reporting $1.5 billion in revenue, growing 12% operationally [22][24] - The livestock portfolio achieved $2.8 billion in revenue, reflecting 8% organic operational growth, driven by broad-based growth across geographies and species [24][30] - Companion animal diagnostics delivered 13% operational revenue growth for the year, supported by the launch of new products [16][23] Market Data and Key Metrics Changes - International markets contributed significantly, with 8% organic operational revenue growth, while the U.S. delivered 4% organic operational growth [7][21] - The international companion animal business grew 7% operationally, driven by the Simparica and key dermatology franchises [28][30] - Livestock performance was particularly strong in the Brazilian cattle market, with broad-based growth across all core species [30][37] Company Strategy and Development Direction - The company is focused on advancing long-acting approvals and maintaining a robust pipeline to extend growth opportunities [8][19] - Strategic actions are being taken to sustain growth through competition, including optimizing channel mix and reinforcing scientific leadership [9][10] - The company aims to leverage its diverse portfolio and innovative capabilities to drive long-term growth and value creation [20][46] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are economic pressures affecting pet owners, demand for animal health services remains strong [10][71] - The company expects gradual improvement in the macro environment as it moves through 2026, with guidance for 2026 set at 3%-5% organic operational revenue growth [18][42] - Management remains confident in the long-term fundamentals of the livestock market, driven by increasing protein consumption and favorable producer economics [18][30] Other Important Information - The company completed a convertible bond offering to support a $1.75 billion common stock buyback while maintaining a strong balance sheet [42] - A multi-year initiative to transition the ERP system is underway, aimed at enhancing operational efficiency and insight [38] Q&A Session Summary Question: Competition and Pricing Dynamics for 2026 - Management acknowledged the competitive landscape and the impact of new product launches on growth, particularly in the dermatology space [50][51] - Price increases are expected to return to a normal range of 2%-3%, with volume contributing to growth as well [52] Question: U.S. Companion Animal Operational Growth - Management indicated that the guidance incorporates current market conditions and the strength of the company's portfolio, despite competitive pressures [55][56] - The demand for animal health remains resilient, with consumers prioritizing spending on their pets [56][71] Question: Dynamics of Simparica Franchise Growth - The Simparica franchise continues to lead in the U.S. market, with significant room for expansion despite recent lower growth rates [62] - Management emphasized the importance of maintaining a strong market position and adapting to competitive pressures [62] Question: Revenue Recognition and Accounting Dynamics - Management clarified that operational changes have led to some revenue recognition shifts, which are factored into the guidance for 2026 [61][63] - The one-month lag in revenue recognition will be addressed with the implementation of fiscal year alignment in early 2026 [61][63]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported global revenue of $9.5 billion, growing 2% on a reported basis and 6% on an organic operational basis, with 4% from price and 2% from volume [20][21] - Adjusted net income grew 6% on a reported basis and 7% on an organic operational basis to $2.8 billion [20][21] - Full year adjusted gross margin of 71.9% grew 120 basis points on a reported basis, with foreign exchange having a favorable impact of 80 basis points [40] Business Line Data and Key Metrics Changes - The companion animal portfolio grew 5% operationally in 2025, with the Simparica franchise reporting $1.5 billion in revenue, growing 12% operationally [21][22] - The livestock portfolio delivered 8% organic operational revenue growth for the year, with $2.8 billion in revenue [24][30] - Companion animal diagnostics delivered broad-based 13% operational revenue growth for the year [14][23] Market Data and Key Metrics Changes - International markets contributed significantly, with 8% organic operational revenue growth, while the U.S. delivered 4% organic operational growth [5][20] - International companion animal grew 7% operationally, driven by the Simparica and key dermatology franchises [27] - International livestock grew 10% on an organic operational basis, with strong performance in the Brazilian cattle market [30] Company Strategy and Development Direction - The company is focused on advancing long-acting approvals and maintaining a robust pipeline to extend growth [6][18] - Strategic actions are being taken to sustain growth through competition, including optimizing channel mix and increasing reach with veterinarians [8][19] - The company aims to leverage its diverse portfolio and robust pipeline, with 12 potential blockbusters in development [18][19] Management Comments on Operating Environment and Future Outlook - Management noted that the operating environment is dynamic, with macroeconomic pressures affecting consumer behavior, particularly among Gen Z and millennial pet owners [6][9] - Despite near-term headwinds, management remains confident in the long-term fundamentals of the animal health market, expecting gradual improvement in 2026 [9][17] - Guidance for 2026 includes organic operational revenue growth of 3%-5% and adjusted net income growth of 3%-6% [42][43] Other Important Information - The company is transitioning its ERP system to enhance operational efficiency and align fiscal years globally [39][40] - A convertible bond offering supported a $1.75 billion common stock buyback, returning over $3.2 billion to shareholders through buybacks and dividends [42] Q&A Session Summary Question: Competition and Pricing Strategy for 2026 - Management acknowledged the competitive landscape and the impact of new product launches on growth, particularly in the dermatology space [48][50] - Price increases are expected to return to a normal range of 2%-3%, with volume contributing to growth as well [52] Question: U.S. Companion Animal Operational Growth - Management indicated that the guidance incorporates current market conditions and the strength of their portfolio, despite competitive pressures [56][57] Question: Dynamics of Simparica Trio Growth - Management highlighted that Simparica Trio remains a leading product with significant room for expansion, despite recent lower growth [61][63]

Core Insights - Zoetis, Inc. (ZTS) is anticipated to exceed expectations in its fourth-quarter 2025 earnings report, scheduled for February 12, 2026, with revenue estimates at $2.37 billion and earnings per share (EPS) at $1.40 [1][5] Group 1: Revenue Expectations - The Zacks Consensus Estimate for U.S. segment revenues is projected at $1.27 billion, likely reflecting a decrease from the previous year due to lower sales of companion animal products [3][5] - International segment revenues are expected to rise to $1.06 billion, driven by increased sales of companion animal products [4][5] Group 2: Product Performance - Sales of companion animal products, particularly from the parasiticides portfolio (including Simparica and Revolution) and key dermatology products (Apoquel and Cytopoint), are expected to contribute positively to revenues in both U.S. and International segments [7] - However, sales of monoclonal antibody products for osteoarthritis pain (Librela for dogs and Solensia for cats) are anticipated to decline in the U.S. due to concerns over side effects, potentially offsetting gains from other product categories [8] Group 3: Regulatory Developments - The FDA approved a new indication for Zoetis' Simparica Trio in 2025, which is expected to enhance sales by preventing flea tapeworm infections in dogs [10] Group 4: Historical Performance - Zoetis has a strong earnings surprise history, having surpassed estimates in each of the last four quarters with an average surprise of 5.37% [13]

Core Viewpoint - Zoetis is set to release its fourth quarter and full year 2025 earnings on February 12, with investor sentiment hinging on the alignment of guidance updates with current expectations [1][5]. Earnings Expectations - The sell-side forecasts predict revenue of $2.36 billion and earnings of approximately $1.40 per share, indicating a year-over-year revenue growth of 1.9% and flat earnings [5]. - Historically, Zoetis has beaten earnings expectations in the last four quarters, and the lowered expectations from the previous quarter may create an opportunity for a positive surprise [6]. Investor Sentiment and Risks - Despite the potential for a positive earnings surprise, there remains a risk that investors may react negatively to the company's outlook, especially if negative macro trends affecting the livestock business persist [7][8]. - Following the previous earnings release in November, Zoetis shares have declined by 11%, indicating lingering investor concerns [8]. Long-term Outlook - The long-term prospects for Zoetis are considered promising, as the company is a leader in the animal healthcare industry with a strong track record of earnings and dividend growth over the past decade [9]. - However, challenges such as headwinds related to its osteoarthritis treatments for pets have led to valuation compression [9].

Core Insights - The fourth-quarter 2025 reporting cycle for the Medical sector is commencing, with major firms expected to release earnings results in the coming weeks, primarily in the pharma/biotech and medical device segments [1] - Johnson & Johnson's strong performance has set a positive tone, while Roche faced challenges due to unfavorable foreign-exchange impacts, particularly from a weak U.S. dollar [1] - Sanofi reported mixed results, beating earnings estimates but slightly missing sales expectations [1] Earnings Trends - As of January 28, 11.7% of Medical sector companies, representing 26% of the sector's market capitalization, have reported quarterly earnings, with 42.9% beating both earnings and revenue estimates [2] - Year-over-year earnings decreased by 15.5%, while revenues increased by 10.3% [2] - Overall, fourth-quarter earnings for the Medical sector are expected to decrease by 2.4%, while sales are projected to rise by 8.7% compared to the previous year [3] Company Highlights - **Zoetis (ZTS)**: Expected to report earnings on February 12, with a consensus estimate of $1.40 per share and revenues of $2.37 billion. The company has an Earnings ESP of +0.84% and a Zacks Rank of 3. Recent performance has been driven by strong demand for companion animal products, although sales of certain monoclonal antibody products may have declined [7][8] - **Pacira BioSciences (PCRX)**: Anticipated to report earnings soon, with a consensus estimate of 85 cents per share and revenues of $196.99 million. The company has an Earnings ESP of +7.38% and a Zacks Rank of 2. Revenue growth is expected from its pain-management product, Exparel, and other products [9][10] - **Apellis Pharmaceuticals (APLS)**: Expected to report earnings soon, with a consensus estimate of a loss of 41 cents per share and revenues of $194.37 million. The company has an Earnings ESP of +4.52% and a Zacks Rank of 3. Revenue growth is likely driven by its geographic atrophy drug, Syfovre [11][12] - **Acadia Pharmaceuticals (ACAD)**: Set to report earnings soon, with a consensus estimate of 12 cents per share and revenues of $292.64 million. The company has an Earnings ESP of +14.92% and a Zacks Rank of 3. Revenue growth is expected from its lead drug, Nuplazid, and its second product, Daybue [13][14] - **Denali Therapeutics (DNLI)**: Expected to report a loss of 75 cents per share and revenues of $18.47 million. The company has an Earnings ESP of +6.11% and a Zacks Rank of 3. Revenue expectations are based on collaboration revenues, with updates on pipeline programs anticipated [15][16]